Jaguar health enters exclusive crofelemer revenue sharing license and commercialization agreement with quadri pharmaceuticals store for rare intestinal failure diseases in middle east markets

Quadri pharma will cover 50% of the costs of development activity up to a capped dollar contribution jaguar to host virtual educational webinar on intestinal failure with leading gastroenterologists and nutrition experts november 8th from 1:00 pm to 2:30 pm est; click here to register for the webinar san francisco, ca / accesswire / november 2, 2023 / napo pharmaceuticals (napo), a jaguar health, inc. (nasdaq:jagx) family company, today announced that it has entered a revenue sharing license and commercialization agreement (the "agreement") with quadri pharmaceuticals store llc (quadri pharma) that grants quadri pharma exclusive promotional, commercialization, and distribution rights for the rare disease indications of microvillus inclusion disease (mvid), other congenital diarrheal disorders, and short bowel syndrome (sbs) with intestinal failure for a powder formulation of crofelemer for oral solution in multiple middle east countries, following regulatory approval to market crofelemer for these indications. in addition, the agreement grants quadri pharma exclusive rights to distribute the powder formulation of crofelemer for the specified indications through named patient programs in the specified middle east countries following regulatory guidelines.
JAGX Ratings Summary
JAGX Quant Ranking